Insider Selling: Artivion (NYSE:AORT) SVP Sells $114,494.92 in Stock

Artivion, Inc. (NYSE:AORT) SVP Marshall Stanton sold 2,566 shares of the firm’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $44.62, for a total value of $114,494.92. Following the completion of the sale, the senior vice president directly owned 61,634 shares of the company’s stock, valued at approximately $2,750,109.08. This trade represents a 4.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Artivion Stock Up 0.3%

NYSE:AORT opened at $45.71 on Friday. The business’s fifty day moving average price is $42.69 and its 200 day moving average price is $36.18. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of -108.84 and a beta of 1.65. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $48.04.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.16 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The firm had revenue of $113.39 million during the quarter, compared to analyst estimates of $110.71 million. The firm’s revenue was up 18.9% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Artivion

Several institutional investors and hedge funds have recently modified their holdings of AORT. Aster Capital Management DIFC Ltd boosted its holdings in Artivion by 402.3% in the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after purchasing an additional 519 shares in the last quarter. MCF Advisors LLC raised its holdings in Artivion by 109.3% during the first quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock valued at $29,000 after buying an additional 614 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after buying an additional 538 shares during the last quarter. State of Wyoming bought a new stake in shares of Artivion during the 3rd quarter worth about $80,000. Finally, Quadrant Capital Group LLC acquired a new position in shares of Artivion during the 3rd quarter valued at about $92,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

Analyst Upgrades and Downgrades

AORT has been the topic of a number of research analyst reports. Canaccord Genuity Group boosted their price objective on shares of Artivion from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Needham & Company LLC lifted their target price on shares of Artivion from $50.00 to $58.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Wall Street Zen upgraded shares of Artivion from a “buy” rating to a “strong-buy” rating in a report on Saturday. Citigroup reiterated an “outperform” rating on shares of Artivion in a report on Friday, October 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, October 8th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.11.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.